Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
65 /100
HIGH RISK
Score updated Oct 13, 2026

ACRS — Aclaris Therapeutics, Inc. Dilution Risk Tracker

Track ACRS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ACRS — Get alerts when the score changes →

As of October 13, 2026, Aclaris Therapeutics, Inc. (ACRS) has a DilutionWatch DilutionScore of 65/100, rated HIGH dilution risk. Aclaris Therapeutics, Inc. has a market capitalization of $529.92M, 147.20M shares outstanding, 139 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
52
💰 Cash Runway
95
📊 Float Risk
22
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 34%
💰 Capital Raise model 55%
• Critical: only 2.9 months cash remaining
🔄 Reverse Split model est. 15%
• Only 3 months cash — financial pressure
📉 Score Deterioration model 10%
• Score in HIGH risk zone (65/100)
🔔 Track ACRS — Get forecast alerts →

Market Data

Market Cap$529.92M
Shares Outstanding147.20M
Float113.21M
Cash$19.17M
Debt$10.73M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore65/100DilutionWatch score record
Shares Outstanding147.20MVerified float table or market cache
Public Float113.21MVerified float table or market cache
Market Cap$529.92MMarket data cache
Cash Runway2.9 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 3, 8-K 2, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 53.1% shares (2026Q1 vs prior)
139 institutional holders · 134.20M shares
#1 BML Capital Management, LLC 14.25M shares
#2 Vivo Capital, LLC 13.33M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 10.33M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest18.19M
Days to Cover6.5
% of Float16.1%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-02-26
xbrl XBRL CONVERTIBLE 2024-02-27
4 INSIDER TRANSACTION 2026-04-27
8-K 8K EVENT 2026-03-11
8-K 8K EVENT 2026-03-10
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual ACRS Dilution Snapshot

Aclaris Therapeutics, Inc. (ACRS) has a DilutionScore of 65/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

ACRS's DilutionScore is currently 65/100 (High risk), with 1 score change tracked over 89 days. The score improved from 50/100 (Medium risk).

Period Score Risk Level Duration
Aug 22 – Oct 13, 202665/100HIGH53 days
Jul 16 – Aug 21, 202650/100MEDIUM36 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

ACRS shares outstanding have increased 28.9% from 108.35M (Mar 2026) to 139.66M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 19, 2026139.66M113.21M▲ 7.22%
May 17, 2026139.66M105.58M▲ 9.19%
May 12, 2026139.66M96.69M▲ 15.81%
May 09, 2026139.66M83.49M▼ 0.03%
May 02, 2026139.66M83.51M▲ 0.53%
Apr 10, 2026121.09M83.07M▼ 7.38%
Mar 21, 2026121.09M89.69M▼ 8.29%
Mar 17, 2026121.09M97.80M▲ 1.01%
Mar 14, 2026121.09M96.82M▲ 2.65%
Mar 05, 2026108.35M94.32M▲ 3.25%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track ACRS Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment ACRS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking ACRS — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ACRS
ACRS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.